2024-10-06 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**Company Overview:** Eli Lilly and Co. is a global pharmaceutical company that researches, develops, manufactures, and markets prescription medicines and other healthcare products.

**1. Performance Comparison to S&P 500 (VOO):**

* **Cumulative Return (LLY):** 850.0
* **Cumulative Return (VOO):** 131.01
* **Current Return Difference:** 718.99
* **Relative Divergence:** 89.32 (This means LLY's performance has been stronger than VOO over the past period, exceeding 90% of the observed historical performance differences).

**2. Recent Price Movement:**

* **Closing Price:** 885.55
* **5-Day Moving Average:** 885.45
* **20-Day Moving Average:** 907.83
* **60-Day Moving Average:** 896.13

**3. Technical Indicators Analysis:**

* **RSI:** 32.41 (Indicates that the stock is currently in oversold territory, potentially suggesting a short-term buying opportunity)
* **PPO:** -0.51 (Suggests a downtrend in price momentum)
* **Delta_Previous_Relative_Divergence:** -4.81 (Short-term downtrend in relative divergence, indicating potential for a pullback from the current price)
* **Expected Return:** 6.68% (This represents the potential for exceeding S&P 500 returns over the next 5 years)

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

* **Latest Earnings:** 3.29 EPS and 11.30 B$ in revenue.  (Analysts' expectations should be reviewed for a more comprehensive analysis).

**5. News and Recent Events:**

* **Recent Market Outlook:** Eli Lilly is expected to continue its strong performance, driven by its growing portfolio of innovative drugs, particularly in diabetes and oncology. The company is also expected to benefit from a favorable regulatory environment. 
* **Analyst Opinions:**  Analysts generally remain optimistic about LLY's prospects, with a majority issuing "Buy" or "Overweight" ratings. 
* **Performance Highlights:**  LLY has been a consistent performer in recent years, outperforming the market consistently.  

**6. Comprehensive Analysis:**

Eli Lilly and Co. (LLY) has consistently outperformed the S&P 500 (VOO), with a strong current return difference.  While recent price movement suggests a potential pullback, the technical indicators point to oversold conditions and a possible buying opportunity.  The company's strong earnings and favorable market outlook suggest continued growth potential.  

**7. Recommendations:**

Based on the analysis, LLY presents a compelling investment opportunity.  The company's strong performance, favorable market outlook, and analysts' positive sentiment suggest continued growth potential.  However, investors should monitor the stock's recent price movement and technical indicators for signs of a potential pullback before making investment decisions.